Retatrutide Protocol
Dosing & Research
Last Updated: April 22, 2026
Obesity and diabetes trials, Triple incretin pharmacology, Weight-loss studies, Cardiometabolic disease research
Evidence Level
Human Clinical Data Available
Species Studied
Human • Rat • Mouse
Half-Life
~6 Days
Administration
Subcutaneous
Frequency
Once Or Twice Weekly, Same Day Each Week
How It Works
- Obesity and diabetes trials
- Triple incretin pharmacology
- Weight-loss studies
- Cardiometabolic disease research
Dosing Structure
Dose
0.5–2.0 mg weekly
Frequency
Once Or Twice Weekly, Same Day Each Week
Notes
1x Weekly titration: Week 1-4: 2mg | Week 5-8: 4mg | Week 9-12: 6mg | Week 13-16: 8mg | Week 17+: 8-12mg. 2x Weekly titration: Week 1-4: 1mg | Week 5-8: 2mg | Week 9-12: 3mg | Week 13-16: 4mg | Week 17+: 4-6mg. *First-time GLP-1 users should consider starting at 1mg per week. No need to increase dose if experiencing benefits. Inject: Abdomen, thigh, upper arm (rotate weekly). Any time of day, same day each week. Typically follows a weekly titration schedule.
Example Protocols
Dose: 0.5–2.0 mg weekly
Frequency: Once Or Twice Weekly, Same Day Each Week
Duration: 8-48 weeks
Off Period: Not listed
Protocol Notes
1x Weekly titration
Week 1-4: 2mgWeek 5-8: 4mgWeek 9-12: 6mgWeek 13-16: 8mgWeek 17+: 8-12mg
2x Weekly titration
Week 1-4: 1mgWeek 5-8: 2mgWeek 9-12: 3mgWeek 13-16: 4mgWeek 17+: 4-6mg
•
*First-time GLP-1 users should consider starting at 1mg per week.
•
No need to increase dose if experiencing benefits.
•
Inject: Abdomen, thigh, upper arm (rotate weekly).
•
Any time of day, same day each week.
•
Typically follows a weekly titration schedule.
Research & Studies
Loading citations…
- Curated References
- CuratedPubMedPMID 37351564Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes↗N Engl J Med · 2023 · Jastreboff AM, Kaplan LM, Frías JP, et al.dosingphase-2obesityhuman
- CuratedPubMedPMID 37351563Triple-hormone-receptor agonist retatrutide for obesity - a Phase 2 trial↗N Engl J Med · 2023 · Hartman ML, Sanyal AJ, Loomba R, et al.obesityphase-2efficacyhuman
- CuratedPubMedPMID 38557299Retatrutide Phase 2b results: hepatic fat fraction and cardiometabolic markers↗Nat Med · 2024 · Loomba R, Hartman ML, Lawitz EJ, et al.livermetabolicphase-2human
Research Feedback
0 approved
For research discussion only. Community feedback is moderated and shown here as aggregated insights after approval.
Be the first to submit research feedback for this peptide.
Approved submissions will appear here as aggregated insights.